The Readout LOUD - Page 2 of 5

Listen: Google’s data grab, problematic genetic testing, & the perils of biotech Twitter

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: An uncertain Alzheimer’s idea, blockbuster fish oil, & a little self-indulgence

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Drugs that don’t work, wearables in the desert, & excess ‘innovation’

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Every angle on Biogen’s shocking Alzheimer’s news

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Pharma’s future in China, CRISPR meets Netflix, & where VC dollars come from

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Relitigating Vioxx, industry growing pains, & how biotech VC works

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Congressional paralysis, drug shortages, & biotech’s foul mood

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Vaping upheaval, DNA test dynamics, & the future of genome editing

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Unicorn growth spurts, Amgen’s future, & mice on Twitter

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Pelosi’s drug pricing plan, Moderna’s mRNA drug factories, and a DIY disease cure

By Adam Feuerstein and Rebecca Robbins

The Readout LOUD

A cyborg magician explains why she implanted 26 microchips and magnets in her body

By Rebecca Robbins

The Readout LOUD

Listen: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Purdue, J&J, and a week of big opioid crisis news

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: The serious side of spit kits, how BiTEs leave a mark, & Sarepta’s sluggish study

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Novartis and the no good, very bad week

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Canadian pills, corporate jets, & racists with spit kits

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Vertex’s regime change, the return of Ebola, & the rise of digital health

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Elon Musk’s monkey cyborg, Gilead’s shifting future, & an app for anxiety

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: A whirlwind week in Washington, Sean Parker’s mansion, & remembering a resonant voice in biotech

By Damian Garde and Rebecca Robbins

The Readout LOUD

Listen: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

By Damian Garde and Adam Feuerstein

The Readout LOUD

Listen: A controversial desire drug, courtroom genealogy, & the quest for longer life

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: Biohacking meets bureaucracy, and the latest twist in CRISPR world

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Readout LOUD

Listen: A special episode from the halls of the ASCO meeting

By Adam Feuerstein and Matthew Herper

Listen: The decade in breakthrough drugs, the year in bad CEOing, and the viruses that cure disease

Listen: The future of CAR-T, an alarming cancer trend, and Sarepta’s FDA legacy

Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep

Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit

Listen: Google’s data grab, problematic genetic testing, & the perils of biotech Twitter

Listen: An uncertain Alzheimer’s idea, blockbuster fish oil, & a little self-indulgence

Listen: Drugs that don’t work, wearables in the desert, & excess ‘innovation’

Listen: Every angle on Biogen’s shocking Alzheimer’s news

Listen: Pharma’s future in China, CRISPR meets Netflix, & where VC dollars come from

Listen: Relitigating Vioxx, industry growing pains, & how biotech VC works

Listen: Congressional paralysis, drug shortages, & biotech’s foul mood

Listen: Vaping upheaval, DNA test dynamics, & the future of genome editing

Listen: Unicorn growth spurts, Amgen’s future, & mice on Twitter

Listen: Pelosi’s drug pricing plan, Moderna’s mRNA drug factories, and a DIY disease cure

A cyborg magician explains why she implanted 26 microchips and magnets in her body

Listen: Pharma existentialism, mainstreaming cyborgs, & FDA palace intrigue

Listen: Purdue, J&J, and a week of big opioid crisis news

Listen: Sarepta keeps a secret, an online army mobilizes, & China embraces biotech

Listen: The serious side of spit kits, how BiTEs leave a mark, & Sarepta’s sluggish study

Listen: Novartis and the no good, very bad week

Listen: Canadian pills, corporate jets, & racists with spit kits

Listen: Vertex’s regime change, the return of Ebola, & the rise of digital health

Listen: Elon Musk’s monkey cyborg, Gilead’s shifting future, & an app for anxiety

Listen: A whirlwind week in Washington, Sean Parker’s mansion, & remembering a resonant voice in biotech

Listen: The future of AbbVieGan, the dogma of amyloid, & some questionable biotech marketing

Listen: A controversial desire drug, courtroom genealogy, & the quest for longer life

Listen: Biohacking meets bureaucracy, and the latest twist in CRISPR world

Listen: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party

Listen: A special episode from the halls of the ASCO meeting